Categories: News

Total number of voting rights and capital on January 31, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

        

Total number of voting rights and capital on January 31, 2024

January 31, 2024
Company announcement No. 05

 

Referring to company announcement 02, on January 29, 2024, where Novozymes A/S (“Novozymes”) announced the completion and final registration with the Danish Business Authority of the statutory merger between Novozymes and Chr. Hansen Holding A/S, the share capital has been increased by nominally DKK 374,597,292 from DKK 562,000,000 to DKK 936,597,292 through the issuance of a total of 187,298,646 new Novozymes B-shares in the denomination of DKK 2 each.

Following the above, and pursuant to Article 32 of the Danish Capital Markets Act, it is hereby announced that the total share capital as of today consists of nominally DKK 936,597,292 comprising a total of 468,298,646 shares, divided into 53,743,600 A shares and 414,555,046 B shares with a nominal value of DKK 2 each and a total of 1,903,982,092 voting rights.

  Nominal Value, DKK Number of shares
A shares 107,487,200 53,743,600
B shares 829,110,092 414,555,046
Total 936,597,292 468,298,646

Contact information
Investor Relations    
Tobias Bjorklund +45 3077 8682 tobb@novonesis.com
Anders Enevoldsen +45 5350 1453 adev@novonesis.com

Media Relations

   
Lina Danstrup +45 3077 0552 lind@novonesis.com
     

 

Attachment

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

18 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

18 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

21 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

21 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

21 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

21 hours ago